Xaluritamig vs Other Treatments for Prostate Cancer
Trial Summary
Xaluritamig is unique because it is an immune therapy that targets a specific protein (STEAP1) found in prostate cancer cells, helping the body's T-cells to attack and kill these cancer cells. This approach is different from traditional treatments as it specifically engages the immune system to fight the cancer.
1341112In a study with 97 patients having advanced prostate cancer, Xaluritamig showed promising results, with 49% of patients experiencing a significant drop in prostate-specific antigen levels and 24% showing an objective response to the treatment. These results were even better at higher doses, suggesting the drug's potential effectiveness.
256712In a study with 97 patients, the most common side effects of Xaluritamig were cytokine release syndrome (a reaction that can cause fever and low blood pressure) in 72% of patients, fatigue in 45%, and muscle pain in 34%. These side effects were mostly seen during the first treatment cycle and improved with premedication and adjusted dosing.
7891012The trial protocol does not specify if you must stop taking your current medications, but it does require that you have not had any anticancer therapy, immunotherapy, or investigational agent within 4 weeks before starting the study treatment, except for ongoing androgen suppression therapy.
Eligibility Criteria
This trial is for adults with advanced prostate cancer that has spread and resisted treatment despite hormone therapy. They must have a confirmed diagnosis, show signs of progression on scans or rising PSA levels, and have previously received specific prostate cancer treatments but not more than one chemotherapy regimen in the castrate-resistant setting.Inclusion Criteria